Prothrombin complex concentrate in the management of major bleeding induced by oral anticoagulant therapy.
Saudi Med J
; 43(2): 213-217, 2022 Feb.
Article
en En
| MEDLINE
| ID: mdl-35110348
ABSTRACT
OBJECTIVES:
To share clinical data on the efficacy of 4F-PCC in the treatment of major bleeding caused by warfarin, dabigatran, and rivaroxaban.METHODS:
This is a retrospective study of patients admitted to King Fahad Medical City, Riyadh, Saudi Arabia with major bleeding caused by oral anticoagulants and treated with 4-factor prothrombin complex concentrate (4F-PCC). The International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee criteria were used to evaluate the effectiveness of PCCs.RESULTS:
A total of 22 patients were included in the study. Ten of the events were caused by gastrointestinal bleeding (46%). In the majority of patients, anticoagulation was prescribed for stroke prevention, atrial fibrillation, and venous thromboembolism. The median international normalized ratio was significantly lower before and after PCC administration (p<0.001). In patients treated with 4-factor PCC, the rate of thromboembolic events was 0%. The hemostatic effectiveness of PCC was effective in 19 patients. During treatment, no clinically significant bleeding complications occurred.CONCLUSION:
Prothrombin complex concentrate can effectively reverse the effects of warfarin and rivaroxaban in patients with major bleeding, but only partially reverses the effect of dabigatran.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Factores de Coagulación Sanguínea
/
Anticoagulantes
Tipo de estudio:
Observational_studies
Límite:
Humans
Idioma:
En
Revista:
Saudi Med J
Año:
2022
Tipo del documento:
Article